Search

Your search keyword '"Giovanni Della Porta, Matteo"' showing total 10 results
Start Over Author "Giovanni Della Porta, Matteo"
10 results on '"Giovanni Della Porta, Matteo"'

1. P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML

Author

Minetto, Paola, primary, Guolo, Fabio, additional, Rosellini, Sara, additional, Piciocchi, Alfonso, additional, Marconi, Giovanni, additional, Audisio, Ernesta, additional, Priolo, Giorgio, additional, Papayannidis, Cristina, additional, Martelli, Maurizio, additional, Paoloni, Francesca, additional, Bocchia, Monica, additional, Lanza, Francesco, additional, Lico, Albana, additional, Ciceri, Fabio, additional, Giovanni Della Porta, Matteo, additional, Frigeni, Marco, additional, Giaccone, Luisa, additional, Beltrami, Germana, additional, Borlenghi, Erika, additional, Chiara DI Chio, Maria, additional, Selleri, Carmine, additional, Crea, Enrico, additional, Urbino, Irene, additional, Sartor, Chiara, additional, Minotti, Clara, additional, Arena, Valentina, additional, Nanni, Jacopo, additional, Simonetti, Giorgia, additional, Teresa Bochicchio, Maria, additional, Saglio, Giuseppe, additional, Venditti, Adrianno, additional, Vignetti, Marco, additional, Fazi, Paola, additional, Tedone, Elisabetta, additional, Martinelli, Giovanni, additional, and Massimo Lemoli, Roberto, additional

Published
2023
Full Text
View/download PDF

2. P499: APPLICABILITY OF 2022 CLASSIFICATIONS OF ACUTE MYELOID LEUKEMIA IN THE REAL-WORLD SETTING

Author

Attardi, Enrico, primary, Savi, Arianna, additional, Borsellino, Beatrice, additional, Piciocchi, Alfonso, additional, Cipriani, Marta, additional, Ottone, Tiziana, additional, Fabiani, Emiliano, additional, Divona, Mariadomenica, additional, Travaglini, Serena, additional, Rosaria Pascale, Maria, additional, Durmaz, Arda, additional, Visconte, Valeria, additional, Giovanni Della Porta, Matteo, additional, Venditti, Adriano, additional, P Maciejewski, Jaroslaw, additional, Gurnari, Carmelo, additional, and Teresa Voso, Maria, additional

Published
2023
Full Text
View/download PDF

3. P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL

Author

Marconi, Giovanni, primary, Arslan, Shukaib, additional, Fleming, Shaun, additional, Curti, Antonio, additional, S Blachly, James, additional, Martinelli, Giovanni, additional, Giovanni Della Porta, Matteo, additional, Bajel, Ashish, additional, Sauer, Tim, additional, Crysandt, Martina, additional, Pigneux, Arnaud, additional, Konopleva, Marina, additional, Marmor, Yotvat, additional, Sharma, Shringi, additional, Elgeioushi, Nairouz, additional, Rowe, Emily, additional, Cheung, Patricia, additional, Jahn, Ekaterina, additional, Saeh, Jamal, additional, Tibes, Raoul, additional, Zumla Cader, Fathima, additional, and Jain, Nitin, additional

Published
2023
Full Text
View/download PDF

4. MDS-167 Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS)

Author

Garcia-Manero, Guillermo, Giovanni Della Porta, Matteo, Santini, Valeria, Zeidan, Amer M., Komrokji, Rami S., Li, Jiahui, Pilot, Richard, Kreitz, Sandra, Pozharskaya, Veronika, Keeperman, Karen L., Lai, Yinzhi, Valcarcel, David, Fenaux, Pierre, and Platzbecker, Uwe

Published
2024
Full Text
View/download PDF

5. MDS-166 Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial

Author

Zeidan, Amer M., Platzbecker, Uwe, Giovanni Della Porta, Matteo, Santini, Valeria, Garcia-Manero, Guillermo, Li, Jiahui, Kreitz, Sandra, Pozharskaya, Veronika, Rose, Shelonitda, Lai, Yinzhi, Valcárcel, David, Fenaux, Pierre, Shortt, Jake, and Komrokji, Rami S.

Published
2024
Full Text
View/download PDF

6. Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial

Author

Zeidan, Amer M., Platzbecker, Uwe, Giovanni Della Porta, Matteo, Santini, Valeria, Garcia-Manero, Guillermo, Li, Jiahui, Kreitz, Sandra, Pozharskaya, Veronika, Rose, Shelonitda, Lai, Yinzhi, Valcárcel, David, Fenaux, Pierre, Shortt, Jake, and Komrokji, Rami S.

Published
2024
Full Text
View/download PDF

7. Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS)

Author

Garcia-Manero, Guillermo, Giovanni Della Porta, Matteo, Santini, Valeria, Zeidan, Amer M., Komrokji, Rami S., Li, Jiahui, Pilot, Richard, Kreitz, Sandra, Pozharskaya, Veronika, Keeperman, Karen L., Lai, Yinzhi, Valcárcel, David, Fenaux, Pierre, and Platzbecker, Uwe

Published
2024
Full Text
View/download PDF

8. Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome

Author

Jädersten, Martin, primary, Malcovati, Luca, additional, Dybedal, Ingunn, additional, Giovanni Della Porta, Matteo, additional, Invernizzi, Rosangela, additional, Montgomery, Scott M., additional, Pascutto, Cristiana, additional, Porwit, Anna, additional, Cazzola, Mario, additional, and Hellström-Lindberg, Eva, additional

Published
2008
Full Text
View/download PDF

9. Leukemic transformation of polycythemia vera

Author

Passamonti, Francesco, primary, Rumi, Elisa, additional, Arcaini, Luca, additional, Castagnola, Carlo, additional, Lunghi, Monia, additional, Bernasconi, Paolo, additional, Giovanni Della Porta, Matteo, additional, Columbo, Nora, additional, Pascutto, Cristiana, additional, Cazzola, Mario, additional, and Lazzarino, Mario, additional

Published
2005
Full Text
View/download PDF

10. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.

Author

Zappasodi P, Cattaneo C, Valeria Ferretti V, Mina R, José María Ferreri A, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Salvini M, Bertù L, Stefano Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Maria Scattolin A, Maria Vannucchi A, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, Pinto A, Trentin L, Bocchia M, Galimberti S, Coviello E, Chiara Tisi M, Morotti A, Falini B, Turrini M, Tafuri A, Billio A, Gentile M, Massimo Lemoli R, Venditti A, Giovanni Della Porta M, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Antonio Grossi P, Corradini P, Passamonti F, and Arcaini L

Subjects
Humans, Aged, COVID-19 Testing, Coinfection, COVID-19 complications, Hematologic Neoplasms complications, Lymphoma
Abstract

The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis., (© 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results